Detecting Cancer Earlier Using Circulating Tumor DNA is organized by Physicians' Education Resource, LLC (PER).
Release Date: March 1, 2021
Expiration Date: March 1, 2022
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education (CME) activity is designed to inform health care providers involved in the clinical care of patients with cancer of emerging data surrounding the use of circulating tumor DNA (ctDNA) as a biomarker for early cancer detection. This in-depth program will cover recent updates regarding clinical trials investigating emerging ctDNA assays, including key data and their potential clinical implications for the diagnostic landscape across tumor types.
Upon successful completion of this activity, you should be better prepared to:
• Summarize the scientific rationale for using circulating tumor DNA (ctDNA) as a biomarker for detecting cancer
• Describe the clinical implications of effectively measuring ctDNA for the detection of cancer
• Explain the most recent data surrounding the use of ctDNA for early cancer detection
Toll free Number
Healthcare Management +12 More
AMA PRA Category 1 Credit™ 10
Nursing +1 More
Oncology +1 More
Contact Hours 9